A.M.S. Mayer, Ph.D.
Professor of Pharmacology

Department of Pharmacology
Chicago College of Osteopathic Medicine
Midwestern University
555 31st Street
Downers Grove, IL 60515

 

 

Phone: (630) 515-6951
Fax: (630) 515-6295
E-mail: amayer@midwestern.edu
Home General Public Reviews Clinical Development Seminars Meetings/Courses Links

MARINE PHARMACOLOGY
NATURAL PRODUCTS AND DERIVATIVES
IN CLINICAL DEVELOPMENT

Compound Name Source Chemical Class Company Disease Area Status
Compounds targeting ion channels
Ziconotide (PrialtTM) Cone snail Peptide Neurex Chronic pain FDA approved 2004
AM-336 Cone snail Peptide AMRAD Chronic pain Phase I/II
GTS-21 Nemertine worm Anabaseine-derivative Taiho Alzheimer/
Schizophrenia		 Phase I/II
Compounds targeting enzymes
Protein kinase inhibitors
Bryostatin-1 Bryozoan Polyketide GPC Biotech Cancer Phase II
Proteosome inhibitor
NPI-0052 Bacteria (Actinomycete) Beta-lactone-gamma-lactam Nereus Cancer Phase I
Methionine aminopeptidase inhibitors
LAF-389 Sponge Amino acid derivative Novartis Cancer Phase I
Microtubule-interacting agents
Dolastatin-10 Sea slug Peptide NCI/Knoll Cancer Phase II
ILX-651 Sea slug Peptide IIex Oncology Cancer Phase II
E7389(eribulin) Sponge Halichondrin B analog Eisai Cancer Phase II/III
NPI-2358 Fungi Diketopiperazine Nereus Cancer Phase I
TZT-1027(Soblidotin) Sea slug Peptide Aska Pharmaceuticals Cancer Phase I
E-7974 Sponge Tripeptide Eisai Cancer Phase I
DNA-interactive agents
YondelisTM Sea squirt Tetrahydroisoquinolone PharmaMar/
Johnson & Johnson		 Cancer Approved by EMEA Sept 2007
ZalypsisTM
(PM00 104)		 Mollusc/Sponge Synthetic alkaloid based on Jorumycin PharmaMar Cancer Phase I
Oxidative stress inducers
AplidinTM
(Plitidepsin)		 Sea squirt Cyclic depsipeptide PharmaMar Cancer Phase II
Lysosomotropic compounds
Kahalalide F Sea slug/Alga Cyclic depsipeptide PharmaMar Cancer Phase II
PM02734 Sea slug Depsipeptide PharmaMar Cancer Phase I
Compounds with unknown mechanism of action
IPL-512602 Sponge Steroid Inflazyme/
Aventis		 Inflammation/
Asthma		 Phase II
Compounds targeting GPCRs
Pseudopterosin A-methyl ether (TMO) Soft Coral Diterpene glycoside Terosin Group Inc./Univ. of CA Wound Healing Phase II

Updated 12/14/2007 using by  A.M.S. Mayer, Pharmacology Department, CCOM, Midwestern University, Downers Grove, IL 60515, USA, Email: amayer@midwestern.edu  and  Keith B. Glaser, Global Pharmaceutical R&D, Cancer Research,   Abbott Laboratories,  Abbott Park, IL 60064-6121, USA. Email: Keith.Glaser@abbott.com.
 Revised 11/27/2007 by David J. Newman, D. Phil., Chief, Natural Products Branch, National Cancer Institute,  Frederick, MD, 21701, USA. Email: newmand@mail.nih.gov.
Revised by 11/27/2007 by Barbara Potts, Nereus Pharmaceuticals, Inc.,San Diego, CA  92121. Email: bpotts@nereuspharm.com.
Revised 11/27/2007 by  Robert S. Jacobs, University of California Santa Barbara, Santa Barbara, CA 93106-9610, USA. Email: rsjacobs@chem.ucsb.edu.

Copyright © 2005-2008 Midwestern University. Last Rev. 2/6/2008. Direct questions or comments to Site Coordinator